Table 1.
Demographics and clinical data.
| DMF 2 × 240 mg (n = 20) | HC (n = 15) | |
|---|---|---|
| Age, mean ( ± SD) | 37.6 (8.5) | 36.3 (10) |
| Sex, no. (%) | ||
| Female | 12 (60) | 12 (80) |
| Male | 8 (40) | 3 (20) |
| EDSS, median (IQR) | ||
| Baseline | 1.0 (0–1.5) | – |
| Follow-up | 1.0 (0–1.5) | – |
| Months since MS diagnosis, mean ( ± SD) | 39.3 (59.1) | – |
| Months since DMF start, mean ( ± SD) | 19.2 (12.1) | – |
| Annualized relapse rate 12 months before screening | 0.25 | – |
| DMT before DMF | ||
| None | 18 | – |
| IFN | 2 | – |
| Vaccine, no. (%) | ||
| VaxigripTetra | 2 (10) | 15 (100) |
| Influvac Tetra | 18 (90) | – |
| Mean time from vaccination to follow-up in days ( ± SD) | 29.1 (2.9) | 40.7 (10.8) |
| Lymphocyte count, no. | ||
| >0.91 × 103/L | 15 | – |
| <0.91 × 103/L | 2 | – |
| <0.80 × 103/L | 3 | – |
| <0.50 × 103/L | 0 | – |
DMF, dimethyl fumarate; HC, healthy control; no., number; IFN, interferon beta; DMT, disease-modifying therapy; SD, standard deviation; IQR, interquartile range; EDSS, Expanded Disability Status Scale.